✦ LIBER ✦

Therapeutic apheresis in special populations

✍ Scribed by Rasheed A. Balogun; Adesola Ogunniyi; Kimberly Sanford; Chidi Okafor; Peter I. Lobo; Ghodrat Siami; John Barcia; Andre A. Kaplan

Publisher: John Wiley and Sons
Year: 2010
Tongue: English
Weight: 122 KB
Volume: 25
Category: Article
ISSN: 0733-2459
DOI: 10.1002/jca.20250

No coin nor oath required. For personal study only.

✦ Synopsis

Apheresis procedures in critically ill patients present a number of challenges to the apheresis team and there are myriad beneficial and adverse effects on patients. Plasmapheresis using a 1 blood volume exchange removes up to 63% of plasma solutes, whereas an exchange using 1.5 blood volumes will remove 78% [1]. As a result, there is also removal of toxins, medications, destructive antibodies as well as clotting factors from the peripheral circulation. Cations are also chelated by the commonly used anticoagulant, citrate. The type of replacement fluid chosen can have an additional impact so selection must be carefully considered.

📜 SIMILAR VOLUMES

Therapeutic apheresis in Canada

✍ Gail A. Rock; Carole A. Herbert 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 233 KB

Therapeutic apheresis in neurological di

Therapeutic apheresis in neurological disorders

✍ Robert Weinstein 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 327 KB 👁 2 views

Therapeutic apheresis in rheumatological

Therapeutic apheresis in rheumatological diseases

✍ Max Hamburger; Gayl Rogers 📂 Article 📅 1985 🏛 John Wiley and Sons 🌐 English ⚖ 30 KB 👁 1 views

Dr. Hamburger was asked whether he would recommend the use of cytoxin or lymphacytapheresis first in the treatment of rheumatoid arthritis. He stated that he would recommend lymphacytapheresis first, especially in relatively young patients because of the multiple side effects and the risk of long-te

Category IV indications for therapeutic

Category IV indications for therapeutic apheresis—ASFA fourth special issue

✍ Beth H. Shaz; Michael L. Linenberger; Nicholas Bandarenko; Jeffrey L. Winters; H 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 98 KB

## Abstract The American Society for Apheresis (ASFA) Committee on Clinical Applications systematically and critically reviews published information on the use of therapeutic apheresis in clinical practice. On the basis of this review, selected diseases are assigned one of five categories (category

Status of therapeutic apheresis in Europ

Status of therapeutic apheresis in Europe

✍ Hans J. Gurland 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 English ⚖ 336 KB 👁 2 views

The development and future trend of therapeutic apheresis in Europe was analyzed. Demographic data on its distribution were collected with the help of the marketing departments of four commercial companies. The differences in application in European countries were examined and compared with North Am

Therapeutic apheresis in critically ill

Therapeutic apheresis in critically ill patients

✍ Kimberly W. Sanford; Rasheed A. Balogun 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 61 KB 👁 1 views

## Abstract Therapeutic apheresis procedures in critically ill patients comprises of therapeutic plasma exchange in most cases but also less commonly, erythrocytapheresis (red cell exchange), thrombocytapheresis, or leukocytapheresis. These procedures present a number of challenges to the apheresis